TransCode Therapeutics, Inc. announced the initiation of a formal strategic process led by Tungsten Advisors to explore potential transactions for its oncology portfolio, including its lead candidate TTX-MC138. The actions suggest the company is seeking to maximize value with no plans to continue funding the development of its lead asset.